Janux Therapeutics Inc. Common Stock (JANX)
Stock · NASDAQ · Health Care
$16.51as of 10/16/2026
Price chart
Active signals
JANX Signal Track Record
How signals performed across all stocks →What JANX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 42 | +8.1% | 57% | September 16, 2026 |
| Bollinger Band Breakdown | 28 | +6.3% | 64% | June 2, 2026 |
| Bollinger Band Breakout | 27 | -2.1% | 44% | October 7, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -13.5% | 38% | August 10, 2026 |
| Any 20-session window (baseline) | -1.9% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About JANX
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical tri…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 113
- Website
- www.januxrx.com/
Fundamentals
- 1-day range
- $17.02$17.62
- Market cap
- $981.85M
- P/E (trailing)
- —
- P/E (forward)
- -6.60
- EPS (trailing)
- $-1.64
- Dividend yield
- —
- Beta
- 2.42
- Avg. volume
- 849.1K
How Janux Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
17 analyst ratings
Janux Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- JANXJanux Therapeutics Inc. Common Stock$16.51▼ 4.68%Market cap $981.85MP/E —$12.12$35.34
- OPKOPKO Health Inc. Common Stock$1.53▼ 4.97%Market cap $985.15MP/E —$0.98$1.75
- AVTXAvalo Therapeutics Inc. Common Stock$11.27▼ 6.16%Market cap $989.29MP/E —$12.51$24.27
- GERNGeron Corporation Common Stock$1.17▼ 4.88%Market cap $1.01BP/E —$1.04$2.01
- ANLAdlai Nortye Ltd. American Depositary Shares$11.03▼ 8.77%Market cap $1.01BP/E —$0.879$17.25
- OMEROmeros Corporation Common Stock$16.2▼ 13.78%Market cap $951.74MP/E 10.87$4.06$21.24
- COLLCollegium Pharmaceutical Inc. Common Stock$23.19▲ 0.04%Market cap $944.15MP/E 15.77$21.43$50.79
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| JANX Janux Therapeutics Inc. Common Stock | $981.85M | — | $16.51 | ▼ 4.68% | $12.12$35.34 |
| OPK OPKO Health Inc. Common Stock | $985.15M | — | $1.53 | ▼ 4.97% | $0.98$1.75 |
| AVTX Avalo Therapeutics Inc. Common Stock | $989.29M | — | $11.27 | ▼ 6.16% | $12.51$24.27 |
| GERN Geron Corporation Common Stock | $1.01B | — | $1.17 | ▼ 4.88% | $1.04$2.01 |
| ANL Adlai Nortye Ltd. American Depositary Shares | $1.01B | — | $11.03 | ▼ 8.77% | $0.879$17.25 |
| OMER Omeros Corporation Common Stock | $951.74M | 10.87 | $16.2 | ▼ 13.78% | $4.06$21.24 |
| COLL Collegium Pharmaceutical Inc. Common Stock | $944.15M | 15.77 | $23.19 | ▲ 0.04% | $21.43$50.79 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Janux Therapeutics (JANX) Stock May Look Overvalued After Its 110% RunYahoo · 10/10/2026
- Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?Yahoo · 9/30/2026
- Is Janux’s Dual JANX013–JANX007 Trial Advancing a Durable Precision Oncology Platform for JANX?Yahoo · 9/29/2026
- Janux Therapeutics (JANX) Advances Prostate Cancer Trial While Valuation Still Looks PriceyYahoo · 9/27/2026
- Janux Therapeutics: It's Too Early To Tell If Prostate Cancer Program Can SucceedSeekingAlpha · 9/18/2026
- Janux Therapeutics, Inc. (JANX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - SlideshowSeekingAlpha · 9/17/2026
- The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and JanuxYahoo · 9/16/2026
- 4 Prostate Cancer Drug Stocks to Watch During Awareness MonthYahoo · 9/15/2026
Insider Activity
Insider Actions →- David Alan Campbell · July 31, 2026 · Gift123.8K
- David Alan Campbell · July 8, 2026 · Option Exercise7.0K @ $4.21
- Jake Simson · June 11, 2026 · Grant15.5K
- Jake Simson · June 11, 2026 · Grant5.5K
- Natasha Hernday · June 11, 2026 · Grant15.5K
- Natasha Hernday · June 11, 2026 · Grant5.5K
- Winston Kung · June 11, 2026 · Grant15.5K
- Winston Kung · June 11, 2026 · Grant5.5K
- Ronald W. Barrett · June 11, 2026 · Grant15.5K
- Ronald W. Barrett · June 11, 2026 · Grant5.5K
- RA Capital Healthcare Fund LP · June 11, 2026 · Grant15.5K
- RA Capital Healthcare Fund LP · June 11, 2026 · Grant5.5K
- Vickie L. Capps · June 11, 2026 · Grant15.5K
- Vickie L. Capps · June 11, 2026 · Grant5.5K
- Eric Dobmeier · June 11, 2026 · Grant15.5K
Institutional Ownership
March 31, 2026
- Total shares held
- 58.45M
- Total value held
- $796.63M
- Institutional holders
- 184
- Unknown11.19M
- Unknown5.43M
- Unknown4.20M
- Unknown3.55M
- Unknown2.54M
- Unknown2.46M
- Unknown1.81M
- Unknown1.79M
- Unknown1.60M
- Unknown1.60M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Janux Therapeutics Faces Uncertainty Over Prostate Cancer Program
The company said it is still early to determine if its prostate cancer program will succeed. This uncertainty may weigh on the stock as investors assess the program’s progress. The shares are near a key support level, adding to the caution.
Janux Therapeutics Faces Uncertainty Over Prostate Cancer Program. The company said it is still early to determine if its prostate cancer program will succeed. This uncertainty may weigh on the stock as investors assess the program’s progress. The shares are near a key support level, adding to the caution.